Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience

URN to cite this document:: urn:nbn:de:bvb:355-epub-577541
DOI to cite this document:: 10.5283/epub.57754

Wild, Mirjam G. ; Kreidel, Felix ; Hell, Michaela M. ; Praz, Fabien ; Mach, Markus

; Adam, Matti ; Reineke, David ; Ruge, Hendrik

; Ludwig, Sebastian

; Conradi, Lenard ; Rudolph, Tanja K. ; Bleiziffer, Sabine ; Kellermair, Jörg ; Zierer, Andreas

; Nickenig, Georg ; Weber, Marcel ; Petronio, Anna Sonia ; Giannini, Cristina ; Dahle, Gry ; Rein, Kjell A. ; Coisne, Augustin

; Vincentelli, André ; Dubois, Christophe ; Duncan, Alison ; Quarto, Cesare ; Unbehaun, Axel ; Amat‐Santos, Ignacio ; Cobiella, Javier ; Dumonteil, Nicolas ; Estevez‐Loureiro, Rodrigo

; Fumero, Andrea ; Geisler, Tobias ; Lurz, Philipp ; Mangieri, Antonio ; Monivas, Vanessa ; Noack, Thilo ; Franco, Luis Nombela ; Pinon, Miguel A. ; Stolz, Lukas ; Tchétché, Didier ; Walter, Thomas ; Unsöld, Bernhard ; Baldus, Stephan ; Andreas, Martin

; Hausleiter, Jörg ; von Bardeleben, Ralph S.

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 29 Feb 2024 13:02

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Aims Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real-world data have not yet been reported. This study aimed to assess procedural and 30-day outcomes of TMVI in a real-world patient cohort. Method and results All consecutive patients undergoing implantation of a transapically delivered self-expanding valve at ...